OCGN Stock Overview
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ocugen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.18 |
| 52 Week High | US$2.11 |
| 52 Week Low | US$0.34 |
| Beta | 3.74 |
| 1 Month Change | -35.52% |
| 3 Month Change | 105.18% |
| 1 Year Change | 63.89% |
| 3 Year Change | -89.47% |
| 5 Year Change | n/a |
| Change since IPO | -58.60% |
Recent News & Updates
Recent updates
Ocugen announces peer-reviewed publication on COVID-19 vaccine
Sep 14Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout
Aug 23Ocugen Q2 2022 Earnings Preview
Aug 04Ocugen: A First Take
Jul 18Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
Jul 05Where Will Ocugen Stock Be In 5 Years?
Apr 27Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The Course
Feb 24Ocugen: The Life After COVID-19
Jan 23Shareholder Returns
| OCGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.1% | 1.0% | 1.2% |
| 1Y | 63.9% | 0.7% | 24.9% |
Return vs Industry: OCGN exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: OCGN exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| OCGN volatility | |
|---|---|
| OCGN Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OCGN's share price has been volatile over the past 3 months.
Volatility Over Time: OCGN's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 65 | Shankar Musunuri | www.ocugen.com |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.
Ocugen, Inc. Fundamentals Summary
| OCGN fundamental statistics | |
|---|---|
| Market cap | US$321.66m |
| Earnings (TTM) | -US$63.08m |
| Revenue (TTM) | US$6.04m |
50.3x
P/S Ratio-4.8x
P/E RatioIs OCGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCGN income statement (TTM) | |
|---|---|
| Revenue | US$6.04m |
| Cost of Revenue | US$39.57m |
| Gross Profit | -US$33.54m |
| Other Expenses | US$29.54m |
| Earnings | -US$63.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | -555.62% |
| Net Profit Margin | -1,045.03% |
| Debt/Equity Ratio | 6.9% |
How did OCGN perform over the long term?
See historical performance and comparison